The findings of the study indicate a statistically significant reduction in OS among patients diagnosed with biliary tract cancer who exhibit a high presence of FoxP3+ Tregs (hazard ratio [HR] = 1.34, 95% confidence interval [CI] 1.16 to 1.71; P < .001; see Fig. 2). This evidence concerns the gene FOXP3 and biliary tract cancer.